ICOSL <sup>+</sup> plasmacytoid dendritic cells as inducer of graft-versus-host disease, responsive to a dual ICOS/CD28 antagonist
Djamilatou Adom, Stacey R. Dillon, Jinfeng Yang, Hao Liu, Abdulraouf Ramadan, Kushi Kushekhar, Samantha Hund, A. Leland Albright, Maykala Kirksey, Titilayo Adeniyan, Katherine E. Lewis, Lawrence S. Evans, Rebecca Wu, Steven D. Levin, Sherri Mudri, Jing Yang, Erika Rickel, Michelle Seaberg, Katherine Henderson, Chelsea J. Gudgeon, Martin F. Wolfson, Ryan Swanson, Kristine M. Swiderek, Stanford L. Peng, Keli L. Hippen, Bruce R. Blazar, Sophie Paczesny
Abstract
-pDCs as an aGVHD biomarker and suggest that coinhibition of the ICOSL/ICOS and B7/CD28 axes with one biologic drug may represent a therapeutic opportunity to prevent or treat aGVHD.
Topics & Concepts
InducerAntagonistCD28MedicineImmunologyDual rolePharmacologyDual (grammatical number)Host (biology)DiseaseChemistryCancer researchCell biologyBiologyImmune systemT cellInternal medicineReceptorBiochemistryGeneCombinatorial chemistryGeneticsLiteratureArtImmunotherapy and Immune ResponsesT-cell and B-cell ImmunologyHematopoietic Stem Cell Transplantation